Literature DB >> 18355976

Postradiotherapy morbidity in long-term survivors after locally advanced cervical cancer: how well do physicians' assessments agree with those of their patients?

Ingvild Vistad1, Milada Cvancarova, Sophie Dorothea Fosså, Gunnar B Kristensen.   

Abstract

PURPOSE: Descriptions of late morbidity after radiotherapy in cervical cancer survivors (CCSs) are usually based on observations made by physicians, and rarely by patients themselves. We describe and compare physician-assessed morbidity with patient-rated symptoms more than 5 years after pelvic radiotherapy. METHODS AND MATERIALS: In 147 CCSs treated between 1994 and 1999 at The Norwegian Radiumhospital, morbidity data were regularly documented by physicians at least for 5 years after radiotherapy. Information on patient-rated symptoms was collected by a questionnaire from 91 (62%) of the 147 survivors after a median follow-up time of 96 months (65-131 months). The results were compared with physician-assessed morbidity scores recorded at 5 years, and to selected normative data using descriptive statistics. Physician-assessed morbidity data were modeled using Kaplan-Meier method. Agreement between physician data and patient data was expressed using weighted kappa statistics.
RESULTS: The 5-year Kaplan-Meier estimates of physician-assessed intestinal, bladder, and vaginal morbidity Grade 3-4 were 15%, 13%, and 23%, respectively. The prevalence of patient-rated severe symptoms from these organs was much higher (intestines 45%, bladder 23%, and 58% vaginal discomfort among sexually active CCSs). Poor agreement was confirmed by low values of kappa: For bladder the concordance was slight (kappa = 0.16) and for intestine it was fair (kappa = 0.27). Stress incontinence, diarrhea, nausea, and sexual problems were significantly (p < 0.001) more prevalent when compared with a control sample from the general female population.
CONCLUSIONS: Morbidity is common after pelvic radiotherapy. However, our data indicate that physicians underreport patients symptoms. It is important to incorporate patient-reported outcomes in the evaluation of treatment-related morbidity.

Entities:  

Mesh:

Year:  2008        PMID: 18355976     DOI: 10.1016/j.ijrobp.2007.12.030

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  25 in total

1.  Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications.

Authors:  Stefan Stefanovic; Markus Wallwiener; Uros Karic; Christoph Domschke; Luka Katic; Florin-Andrei Taran; Aleksandra Pesic; Andreas Hartkopf; Peyman Hadji; Martin Teufel; Florian Schuetz; Christof Sohn; Peter Fasching; Andreas Schneeweiss; Sara Brucker
Journal:  Support Care Cancer       Date:  2016-10-17       Impact factor: 3.603

Review 2.  Contemporary quality of life issues affecting gynecologic cancer survivors.

Authors:  Jeanne Carter; Richard Penson; Richard Barakat; Lari Wenzel
Journal:  Hematol Oncol Clin North Am       Date:  2011-12-16       Impact factor: 3.722

3.  The quality-of-life effects of neoadjuvant chemoradiation in locally advanced rectal cancer.

Authors:  Joseph M Herman; Amol K Narang; Kent A Griffith; Mark M Zalupski; Jennifer B Reese; Susan L Gearhart; Nolifer S Azad; June Chan; Leah Olsen; Jonathan E Efron; Theodore S Lawrence; Edgar Ben-Josef
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-10-09       Impact factor: 7.038

Review 4.  Pelvic floor disorders in women with gynecologic malignancies: a systematic review.

Authors:  Aparna S Ramaseshan; Jessica Felton; Dana Roque; Gautam Rao; Andrea G Shipper; Tatiana V D Sanses
Journal:  Int Urogynecol J       Date:  2017-09-19       Impact factor: 2.894

5.  Do clinicians and patients agree regarding symptoms? A comparison after definitive radiochemotherapy in 223 uterine cervical cancer patients.

Authors:  K Kirchheiner; R Nout; J Lindegaard; P Petrič; E V Limbergen; I-M Jürgenliemk-Schulz; C Haie-Meder; R Pötter; W Dörr
Journal:  Strahlenther Onkol       Date:  2012-08-17       Impact factor: 3.621

6.  Bladder and bowel symptoms in cervical and endometrial cancer survivors.

Authors:  Kristine A Donovan; Alice R Boyington; Patricia L Judson; Jean F Wyman
Journal:  Psychooncology       Date:  2014-01-30       Impact factor: 3.894

7.  Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer.

Authors:  Avani D Rao; Elizabeth A Sugar; Daniel T Chang; Karyn A Goodman; Amy Hacker-Prietz; Lauren M Rosati; Laurie Columbo; Eileen O'Reilly; George A Fisher; Lei Zheng; Jonathan S Pai; Mary E Griffith; Daniel A Laheru; Christine A Iacobuzio-Donahue; Christopher L Wolfgang; Albert Koong; Joseph M Herman
Journal:  Pract Radiat Oncol       Date:  2016-05-25

8.  The abandoned radical hysterectomy for cervical cancer: clinical predictors and outcomes.

Authors:  Heidi J Gray; Erin Seifert; Victor G Sal Y Rosas; Katrina F Nicandri; Wui-Jin Koh; Barbara A Goff
Journal:  Obstet Gynecol Int       Date:  2010-04-28

9.  Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes.

Authors:  Ethan Basch; Xiaoyu Jia; Glenn Heller; Allison Barz; Laura Sit; Michael Fruscione; Mark Appawu; Alexia Iasonos; Thomas Atkinson; Shari Goldfarb; Ann Culkin; Mark G Kris; Deborah Schrag
Journal:  J Natl Cancer Inst       Date:  2009-11-17       Impact factor: 13.506

10.  Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06.

Authors:  Jason A Efstathiou; Kyounghwa Bae; William U Shipley; Donald S Kaufman; Michael P Hagan; Niall M Heney; Howard M Sandler
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.